REZOLUTE INC

Rezolute released convincing interim data from the phase-3 upLIFT study for the treatment of tumor-induced hyperinsulinism, prompting analysts to lift their price targets significantly. Maxim sees upside potential of 222%, underscoring heightened growth expectations. With a market capitalization of around $0.3 billion, the report suggests Rezolute could potentially transform into a commercial biotech player with market-dominant prospects. » More on finanzen.net

Rezolute presented expanded and post‑hoc analyses of the phase‑3 sunRIZE study of Ersodetug in congenital hyperinsulinism after the primary endpoint (reduction of self‑monitored hypoglycemia events) was not met. The new data show by continuous glucose monitoring a reduction in daily time in hypoglycemia of more than 50% in the full analysis set and about 60–80% in the per‑protocol set, as well as fewer weekly hypoglycemia events versus placebo. The improvements were nominally significant but did not reach statistical significance for a secondary endpoint at week 24. The FDA has acknowledged the challenges and asked Rezolute to submit more comprehensive study data; the company also highlights solid liquidity and will report quarterly results on May 13. » More on de.investing.com